Berberine goes viral as 'nature's Ozempic'

A cheap over-the-counter supplement called berberine spread across TikTok and other platforms in 2023 under the nickname "nature's Ozempic," pitched as a low-cost stand-in for semaglutide. Clinicians and government reviewers responded quickly, and their conclusion has been consistent: the evidence that berberine produces meaningful weight loss is weak, and the supplement is not a GLP-1 drug.

The American Academy of Family Physicians published a community blog post on July 3, 2023, written by Jennifer Middleton, MD, MPH, noting that semaglutide's cost and intermittent shortages had made it hard for many people to get, and that berberine — an herbal supplement most commonly derived from the berry of the berberis shrub — had become "a social media superstar" as TikTokers touted weight-loss benefits at a fraction of semaglutide's price ^[2]. Her assessment was blunt: rigorous data demonstrating benefit are lacking, and berberine can interact with medications metabolized by the liver ^[2].

What the studies actually show

The human research on berberine is mostly small and focused on blood sugar and cholesterol rather than weight. A very small 2008 pilot study in people with type 2 diabetes showed glucose lowering equivalent to metformin, and a slightly larger randomized trial against placebo found decreases in blood glucose and lipid levels ^[2]. A 2018 systematic review found berberine superior to comparison groups on fasting and after-meal glucose, but the included trials were rated "low to moderate" quality ^[2]. Middleton wrote that these studies measured disease-oriented outcomes on a relatively small scale with methodological concerns, and that there has never been a large-scale randomized or multicenter clinical trial of the kind new diabetes drugs must undergo for FDA approval ^[2].

The Department of Defense's Operation Supplement Safety program put a number on the weight question. One review reported a weight reduction of 0.84 kg — almost 2 pounds — in people with certain diseases who took berberine for up to 18 weeks ^[3]. When low-quality studies were excluded, that reported reduction no longer existed ^[3]. OPSS states flatly that the evidence does not support claims for berberine as the "key to weight loss," that claims of it being "Nature's Ozempic" are exaggerated, and that the safety of long-term use is unknown ^[3]. Its page was listed as current as of December 15, 2025 ^[3].

UCLA Health, in an article published October 22, 2025, reached a similar bottom line while describing the research more favorably in other areas. Senior clinical dietitian Dana Ellis Hunnes, PhD, MPH, RD, said, "There needs to be more gold-standard, randomized, controlled clinical trials to understand the true potential of berberine" ^[1]. The article notes berberine works differently than GLP-1 drugs: rather than mimicking the GLP-1 hormone, it triggers the enzyme AMPK, which controls metabolism and energy ^[1]. Preliminary research suggested reductions in weight, BMI and waist circumference in people with a BMI in the 25–29.9 range, with participants taking 1 gram daily and effects appearing after at least eight weeks — but UCLA says most experts agree the amount of weight lost is unclear and the evidence is inconclusive ^[1].

Why it matters for patients

Berberine is sold as a dietary supplement in the United States, which means the FDA "does NOT have the authority to approve dietary supplements for safety and effectiveness," as the AAFP post quoted ^[2]. It is also impossible to know for certain whether the ingredients listed on a bottle match what is inside ^[2], and OPSS warns that weight-loss products sometimes contain hidden drugs or other potentially harmful ingredients, recommending buyers check for third-party evaluation ^[3].

Side effects reported include diarrhea, constipation, nausea and stomach upset ^[3], plus abdominal pain, bloating and headaches ^[1]. Interactions are a real concern: berberine has known interactions with drugs metabolized by the liver, including metformin ^[2], and UCLA flags anti-rejection drugs taken after organ transplant and the possibility that it could make existing diabetes medication more potent ^[1]. OPSS says berberine should not be taken by anyone who is pregnant, nursing or planning to become pregnant ^[3]; UCLA notes it can cause a buildup of bilirubin that can harm infants ^[1]. Long-term safety data are lacking ^[3].

One practical gap: none of these sources report a head-to-head trial comparing berberine with semaglutide or any GLP-1 drug. How the two compare directly is not yet known.